Catalysts / SGP
Upcoming FDA decisions and readouts we track for SpyGlass Pharma, each with the filing that announced it.
FreeBioList tracks 1 upcoming catalyst for SpyGlass Pharma (SGP, listed on Nasdaq). It concerns BIM-DRS (Open-angle glaucoma and ocular hypertension).
First on the list: the Phase 1/2 readout for BIM-DRS (Open-angle glaucoma and ocular hypertension), guided by the company to Q4 2026.
The row links to an SEC filing (8-K or 6-K). It has been verified by a person reading the filing itself, most recently on 12 Sep 2026. The methodology page explains each status.
Background reading: Clinical trial phases explained: Phase 1 to Phase 4.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| SpyGlass Pharma SGP · Nasdaq | BIM-DRS | Open-angle glaucoma and ocular hypertension | Q4 2026 company guidance |
Phase 1/2 readout | Verified | 8-K exhibit 99.1 ↗ | No |
FreeBioList